Page 5 - Axel Hoos News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours Investigational PD-1 inhibitor is being studied in mismatch repair-deficient solid tumours GlaxoSmithKline’s (GSK) dostarlimab – an investigational PD-1 inhibitor – has demonstrated promising results in patients with heavily pre-treated solid cancer tumours. The updated data comes from cohort F of GSK s GARNET trial, which enrolled patients with mismatch repair-deficient (dMMR) non-endometrial advanced solid cancer tumours. The majority of this cohort had gastrointestinal cancer, with the highest prevalence in colorectal, gastric and small intestinal cancer. Most of the patients in this study were also heavily pre-treated – many had already been treated with two or more prior lines of systemic therapy.

France generalEmma walmsleyThierry andrHal barronAxel hoosSorbonne universityDrug administrationMedical oncologySaint antoine hospitalபிரான்ஸ் ஜநரல்எம்மா வால்ம்ஸ்லிதியரி அன்றுஹால் பரோன்சோர்போன் பல்கலைக்கழகம்மருத்துவ புற்றுநோயியல்துறவி அன்டோயின் மருத்துவமனை